Intellia Therapeutics, Inc (NTLA) — Analysis Summary
Intellia Therapeutics, Inc (NTLA) has a market cap of $1.84B with year-over-year revenue growth of +16.9%. Net margin stands at -609.9%. The stock trades at a P/E ratio of -4.6.
Key Takeaways
- Revenue changed +16.9% year-over-year
- Net margin of -609.9%
- P/E ratio of -4.6
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, NTLA posted revenue growth of +16.9% and trades at a P/E of -4.6.
Intellia Therapeutics, Inc (NTLA)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -711.7% — severe operating losses
Net margin at -672.2% — losses exceed revenue (possible one-time charges)
Revenue declined 12.1% vs the prior period.
The latest filing shows negative free cash flow.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
377
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.